

---

**From:** Board of Pharmacy <pharmacy.subscriberlist@DCA.CA.GOV>  
**Sent:** Monday, June 19, 2017 10:55 AM  
**To:** PHARM-RPH@DCALISTS.CA.GOV  
**Cc:** Pharmacy\_Subscriberlist@DCA  
**Subject:** Recall notice - ImprimisRx

On Thursday June 15, 2017, the Federal Food and Drug Administration notified ImprimisRx CA that one of its suppliers mislabeled an inactive ingredient contained in small quantities in the below-referenced lots. ImprimisRx CA is recalling all affected lots that are within their expiry date.

ImprimisRx CA intends to exchange all affected lots with new prescription medications at no charge.

Immediately examine your inventory and quarantine any products from the above-referenced lots. In addition, if you have further dispensed this product, please identify your customers, and notify them at once of this product recall.

Please immediately check your inventory, quarantine, discontinue distribution of the affected product, and contact your wholesaler for directions.

- **Curcumin Emulsion for Injection**, Lot 03212017@218, Expires on 6/19/2017; Lot 03232017@198, Expires on 6/21/2017; Lot 03292017@278, Expires on 6/27/2017; Lot 04042017@218, Expires on 7/3/2017; Lot 04122017@228, Expires on 7/11/2017; Lot 04132017@148, Expires on 7/12/2017; Lot 04192017@378, Expires on 7/18/2017; Lot 04192017@178, Expires on 7/18/2017; Lot 04242017@188; 7/23/2017
- **Timolol 0.5%- Brimonidine 0.15%- Dorzolamide 1%- Latanoprost 0.005% PF Ophthalmic Solution**, Lot 05092017@28, Expires on 11/5/2017
- **Timolol 0.5% - Latanoprost 0.005% PF Ophthalmic Solution**, Lot 04042017@348, Expires on 10/01/2017
- **Latanoprost 0.005% PF Ophthalmic Solution**, Lot 04042017@328, Expires on 10/01/2017